Early detection of melanoma: The best strategy for a favorable prognosis

Clinics in Dermatology

Volumn 20, Issue 3, 2002, Pages 203-211

  Brenner, Sarah ^a,b   Tamir, Einat ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; DACARBAZINE; INTERLEUKIN 2; MONOCLONAL ANTIBODY; SUNSCREEN;

ADOPTIVE IMMUNOTHERAPY; AGING; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EPILUMINESCENCE MICROSCOPY; EUROPE; FOLLOW UP; HUMAN; LYMPHOCYTE ACTIVATION; MELANOMA; NEUTRON CAPTURE THERAPY; NEW ZEALAND; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; SUN EXPOSURE; SUNBURN;

EID: 0036285343     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(02)00233-X     Document Type: Article

References (76)

1. Update on malignant melanoma in children
2. Subungual melanoma: A review of 93 cases with identification of prognostic variables
3. Malignant melanoma in childhood
4. The risk of melanoma in patients with congenital nevi: A cohort study
5. The incidence of malignant melanoma (0 to 15 years of age) arising in 'large' congenital nevocellular nevi
6. Malignant melanoma: A clinical review
7. Increasing incidence of cutaneous melanoma in Queensland, Australia
8. The melanoma epidemic: More apparent than real?
9. Gender and cutaneous melanoma
10. Investigation of female survival benefit in metastatic melanoma
11. Survival superiority of females with melanoma: A multivariant analysis of 6383 patients exploring the significance of gender in prognostic outcome
12. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen
13. Tamoxifen, β-estradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin
14. 17-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production
15. Androgens regulate bone resorption activity of isolated osteoclasts in vitro
16. Delays in diagnosis and melanoma prognosis, I: The role of patients
17. Malignant melanoma in black Americans: A trend toward improved survival
18. Plantar melanoma: Is the incidence of melanoma of the sole of the foot really higher in blacks than in whites?
19. Subungual melanoma
20. Acral lentiginous melanoma
21. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: An analysis of California cancer registry data, 1988-93
22. Risk factors for the development of malignant melanoma, I: Review of case-control studies
23. Malignant melanoma: A case controlled study of possibly associated factors
24. Neoplasms: Cutaneous melanoma
25. Incidence, risk factors and prevention of melanoma
26. Signs and symptoms of melanoma in older populations
27. Malignant melanoma in the elderly
28. Malignant melanoma: An emerging and preventable medical catastrophe
29. Cutaneous melanoma
30. Staging and prognosis of melanoma
31. Current therapy of cutaneous melanoma
32. Current therapy for cutaneous melanoma
33. Intervention strategy to prevent lethal cutaneous melanoma: Use of dermatologic photography to aid surveillance of high-risk persons
34. Computerized systems to enhance the clinical diagnosis of pigmented cutaneous malignancies
35. The ABCD rule of dermatoscopy: High prospective value in the diagnosis of doubtful melanocytic skin lesions
36. Role of lymphatic mapping and sentinel node biopsy in melanoma detection
37. Surgical treatment of primary melanoma
38. Primary cutaneous malignant melanoma and its precursor lesions: Diagnostic and therapeutic overview
39. Surgical margins for excision of primary cutaneous melanoma
40. Mohs micrographic surgery for the treatment of primary cutaneous melanoma
41. Mohs micrographic surgery using HMB-45 for recurrent acral lentiginous melanoma
42. Rapid HMB-45 staining in Mohs micrographic surgery for melanoma in situ and invasive melanoma
43. HMB-45 staining in benign and malignant melanocytic lesions: A reflection of cellular activation
44. Typical dysplastic, congenital, and Spitz nevi: A comparative immunohistochemical study
45. HMB-45 staining of dysplastic nevi: Support for a spectrum of progression toward melanoma
46. Antibody HMB-45 identifies the cells of blue nevi: An immunohistochemical study on paraffin sections
47. Diagnosis and treatment of metastatic melanoma
48. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
49. Systemic adjuvant treatment of high-risk melanoma: The role of interferon alfa-2b and other immunotherapies
50. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomized trial
51. Immunotherapy of murine sarcomas using lymphokine activated killer cell: Optimization of the schedule and route of administration of recombinant interleukin-2
52. Phase II clinical trial of GM2-KL/QS-21 (GMK) vaccine in patients with malignant melanoma
53. Melanoma peptide vaccine: A randomized phase I evaluation of MART-I, gp 100, and tyrosinase peptide vaccines in patients with malignant melanoma
54. New approaches to treating advanced melanoma
55. Hyperthermic regional perfusion for melanoma of the limbs
56. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma
57. Management of local recurrence, satellites, and in transit metastases of the limbs with isolated perfusion
58. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities
59. Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients
60. Serological markers for melanoma
61. The use of serological tumor markers for malignant melanoma
62. S-100 protein in peripheral blood: A marker for melanoma metastases
63. S100 protein serum levels in cutaneous malignant melanoma
64. Serum S-100 protein as a marker of disease activity in malignant melanoma
65. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers for melanoma progression
66. Prognostic value of serum analyses of S-100 protein β in malignant melanoma
67. Melanoma in the midwestern United States: Experience at the Mayo Clinic
68. A ten-year analysis of demographic trends for cutaneous melanoma: Analysis of 2501 cases treated at the university department of dermatology in Vienna (1990-1999)